Towards a healthier discount procedure.

Abstract:

:Most national guidelines for pharmacoeconomic research prescribe discounting, mostly of money and health against the same rate. There is much debate on whether this is adequate. Two theoretical arguments, the consistency argument of Weinstein and Stason, and the paralyzing paradox of Keeler and Cretin, are mostly responsible for the current standards. However, more recently, several authors have indicated that the basis to claim the necessity of using similar discount rates is rather weak, both practically and theoretically. In terms of finding a new theoretical basis on which to base discount rates for money and, in particular, health, Van Hout has made an important suggestion arguing that the discount rate for health could be based on the expected growth in life expectancy and the diminishing marginal utility related to such additional health. Similarly, Gravelle and Smith argue that if the value of health grows over time, discount rates that are used for costs cannot directly be applied to effects, but should be adjusted downwards.

authors

Klock RM,Brouwer WB,Annemans LJ,Bos JM,Postma MJ

doi

10.1586/14737167.5.1.59

subject

Has Abstract

pub_date

2005-02-01 00:00:00

pages

59-63

issue

1

eissn

1473-7167

issn

1744-8379

journal_volume

5

pub_type

杂志文章
  • Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment.

    abstract::Up to 10% of the adult population in most countries may be affected by chronic bronchitis or chronic obstructive pulmonary disease. The course of the disease is characterized by frequent exacerbations with increased respiratory symptoms. Exacerbations are the most important cause of morbidity and mortality, and signif...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.4.423

    authors: Miravitlles M

    更新日期:2005-08-01 00:00:00

  • Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.

    abstract::Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no internationa...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.49

    authors: Hirsch EB,Tam VH

    更新日期:2010-08-01 00:00:00

  • Health related quality of life impact from rotavirus diarrhea on children and their family caregivers in Thailand.

    abstract:BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,多中心研究

    doi:10.1080/14737167.2018.1386561

    authors: Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

    更新日期:2018-04-01 00:00:00

  • Cost-effectiveness of palivizumab in infancy.

    abstract::Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to re...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.5.445

    authors: Embleton ND,Dharmaraj ST,Deshpande S

    更新日期:2007-10-01 00:00:00

  • How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.

    abstract::In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.859525

    authors: Diaby V,Goeree R

    更新日期:2014-02-01 00:00:00

  • Burden of skin diseases.

    abstract::Skin diseases are among the most common health problems worldwide and are associated with a considerable burden. The burden of skin disease is a multidimensional concept that encompasses psychological, social and financial consequences of the skin disease on the patients, their families and on society. Chronic and inc...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.09.23

    authors: Basra MK,Shahrukh M

    更新日期:2009-06-01 00:00:00

  • The burden of diurnal and nocturnal gastroesophageal reflux disease symptoms.

    abstract:AIMS:To quantify the relationship between the timing of gastroesophageal reflux disease (GERD) symptoms and the burden of illness. PATIENTS & METHODS:Data from the 2010 National Health and Wellness Survey were used. Regression analyses compared non-GERD controls with GERD patients with diurnal symptoms, nocturnal symp...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.11.72

    authors: Wagner JS,DiBonaventura MD,Balu S,Buchner D

    更新日期:2011-12-01 00:00:00

  • National trends in out-of-pocket prescription drug spending among elderly medicare beneficiaries.

    abstract::This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.3.297

    authors: Sambamoorthi U,Akincigil A,Wei W,Crystal S

    更新日期:2005-06-01 00:00:00

  • Quality of care of asthma during pregnancy.

    abstract::The goal of asthma management during pregnancy is to keep the mother symptom free and to prevent complications in the fetus. Asthma is a common chronic condition in pregnancy that, if inadequately treated, has the potential to cause adverse effects for both mother and fetus. Aggressive treatment during pregnancy can d...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.1.67

    authors: Streck MR,Blaiss MS

    更新日期:2006-02-01 00:00:00

  • Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa.

    abstract::The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further progress DU research in Africa. This built on extensive activities from the firs...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1256775

    authors: Massele A,Burger J,Kalemeera F,Jande M,Didimalang T,Kalungia AC,Matshotyana K,Law M,Malone B,Ogunleye O,Oluka M,Paramadhas BD,Rwegerera G,Zinyowera S,Godman B

    更新日期:2017-04-01 00:00:00

  • Measuring the costs and benefits of pharmaceutical expenditures.

    abstract::In response to concerns about the cost burden of medical care in general and rising pharmaceutical costs in particular, a number of recent studies have examined trends in pharmaceutical expenditures. These studies have reached apparently disparate conclusions about factors responsible for rising pharmaceutical costs a...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2.5.467

    authors: Crown WH,Ling D,Berndt E

    更新日期:2002-10-01 00:00:00

  • Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.

    abstract:INTRODUCTION:In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1277144

    authors: Kwon SH,Park SK,Byun JH,Lee EK

    更新日期:2017-08-01 00:00:00

  • Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis.

    abstract:BACKGROUND:This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2019.1632194

    authors: Wijnen BFM,Thielen FW,Konings S,Feenstra T,Van Der Gaag M,Veling W,De Haan L,Ising H,Hiligsmann M,Evers SMAA,Smit F,Lokkerbol J

    更新日期:2020-06-01 00:00:00

  • Non-communicating children's pain checklist: better pain assessment for severely disabled children.

    abstract::Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.3.327

    authors: Breau LM

    更新日期:2003-06-01 00:00:00

  • Cost-effective approaches to influenza prevention and treatment.

    abstract::Influenza, the seventh leading cause of death in the USA, accounts for 35,000 deaths and over 200,000 hospitalizations annually in that country alone. Recent advances in influenza vaccines, diagnosis and treatment have created numerous options for practicing clinicians, as well as economic opportunities for the makers...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.2.141

    authors: Rothberg M

    更新日期:2005-04-01 00:00:00

  • Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).

    abstract:INTRODUCTION:During the past few years, medical-economic evaluation of lung cancers (LCs) has become unavoidable. Total management costs have been rising constantly, with values almost doubling every 10 years. The financial impact will be even greater with the new molecules now marketed. The methodology for these studi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2018.1485099

    authors: Vergnenègre A,Chouaïd C

    更新日期:2018-10-01 00:00:00

  • The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions.

    abstract:BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1282316

    authors: Schepers J,Plaete J,De Bourdeaudhuij I,Annemans L,Simoens S

    更新日期:2017-08-01 00:00:00

  • Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitis.

    abstract:AIM:To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis. PATIENTS AND METHODS:This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.4.337

    authors: Roger A,Fortea J,Mora S,Artés M

    更新日期:2008-08-01 00:00:00

  • Health economics of percutaneous hemodynamic support in the treatment of high-risk cardiac patients: a systematic appraisal of the literature.

    abstract::This article systematically appraises the findings and conclusions derived from six recent studies of the economic impact and relative value of using percutaneous ventricular assist devices to render short-term hemodynamic support to high-risk patients with particular attention to the settings of cardiogenic shock and...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.908714

    authors: Maini B,Scotti DJ,Gregory D

    更新日期:2014-06-01 00:00:00

  • Economic considerations and future directions for lung volume reduction surgery.

    abstract::Chronic obstructive pulmonary disease is a major cause of morbidity and mortality throughout the world. Standard management includes avoidance of causative factors such as smoking, and pharmacological therapy with combinations of inhaled and/or oral bronchodilators and corticosteroids. Lung transplantation is an estab...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.6.729

    authors: Reed A,Williams T,Snell G

    更新日期:2003-12-01 00:00:00

  • Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.

    abstract:OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1411193

    authors: Trigo-Vicente C,Gimeno-Ballester V,Montoiro-Allué R,López-Del Val A

    更新日期:2018-06-01 00:00:00

  • Adenosine and dipyridamole in nuclear imaging: pharmacoeconomic considerations.

    abstract::Adenosine and dipyridamole are coronary vasodilators used in nuclear imaging. The acquisition cost of adenosine is four to ten times higher than dipyridamole. Data suggest comparable sensitivity, although specificity may be lower with dipyridamole. While side effect profiles are similar, fewer patients who receive ade...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2.6.555

    authors: Reddy P

    更新日期:2002-12-01 00:00:00

  • Antibiotics and reduced risk of COPD re-exacerbations.

    abstract::Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.33

    authors: Antoniu SA

    更新日期:2009-08-01 00:00:00

  • Patient-reported outcomes measurements in epilepsy.

    abstract::This review was designed to explore and review the range of patient-reported outcomes used to assess people with epilepsy. Literature searches were conducted through EMBASE.com and supplemented with hand searching of relevant articles. References obtained through hand searches were compared with EMBASE.com citations u...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.4.373

    authors: Stafford M,Gavriel S,Lloyd A

    更新日期:2007-08-01 00:00:00

  • Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.

    abstract:INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2019.1554437

    authors: Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

    更新日期:2019-04-01 00:00:00

  • Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.

    abstract::Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.2.111

    authors: Gladman DD,Brown RE

    更新日期:2008-04-01 00:00:00

  • Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.

    abstract::Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby reducing the risk of thrombocytopenia. Clinical tr...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.3.227

    authors: Wade WE,Spruill WJ

    更新日期:2007-06-01 00:00:00

  • The START study: when to start to treat with inhaled steroids in asthma?

    abstract::Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/14737167.3.3.223

    authors: Antoniu SA

    更新日期:2003-06-01 00:00:00

  • Understanding how information and ICTs can improve health.

    abstract::The 15th International Symposium for Health Information Management Research (ISHIMR) was organized jointly by University Hospital Zurich (Switzerland), the University of St Gallen (St Gallen, Switzerland) and the University of Sheffield (Sheffield, UK). Participants included researchers, healthcare professionals, heal...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1586/erp.11.91

    authors: Bath PA,Sen BA,Raptis DA,Mettler T

    更新日期:2012-02-01 00:00:00

  • The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.

    abstract::The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1080/14737167.2017.1385394

    authors: Novakovic T,Martin AP,Parker M,Ferrario A,Vukovic S,Łanda K,Duba J,Dankó D,Kotsopoulos N,Godman B,Ristic J,Stefanovic D,Tesic D

    更新日期:2017-12-01 00:00:00